PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
-10%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$4.14B
AUM Growth
+$4.14B
(-27%)
Cap. Flow
-$722M
Cap. Flow
% of AUM
-17.44%
Top 10 Holdings %
Top 10 Hldgs %
47.31%
Holding
128
New
20
Increased
20
Reduced
31
Closed
18
Top Buys
| 1 |
Iovance Biotherapeutics
IOVA
|
$53.4M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$45.3M |
| 3 |
Immatics
IMTX
|
$40.7M |
| 4 |
CTNM
Contineum Therapeutics
CTNM
|
$27.6M |
| 5 |
Merus
MRUS
|
$17.8M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$149M |
| 2 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$146M |
| 3 |
Medtronic
MDT
|
$73.9M |
| 4 |
Sarepta Therapeutics
SRPT
|
$68.1M |
| 5 |
Axsome Therapeutics
AXSM
|
$52M |
Sector Composition
| 1 | Healthcare | 99.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CERE
1
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $441M | 10.63% | 10,794,876 | – | – |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $278M | 6.7% | 28,057,456 | – | – |
|
3
Arcellx
ACLX
$3.85B
| $215M | 5.17% | 3,889,739 -43,817 | -1% | -$2.42M |
|
|
4
Iovance Biotherapeutics
IOVA
$807M
| $208M | 5.01% | 25,933,142 +6,660,151 | +35% | +$53.4M |
|
5
Nuvalent
NUVL
$5.52B
| $193M | 4.66% | 2,549,077 -234,377 | -8% | -$17.8M |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $142M | 3.41% | 3,446,579 +178,000 | +5% | +$7.31M |
|
7
Vaxcyte
PCVX
$4B
| $141M | 3.39% | 1,862,608 -70,151 | -4% | -$5.3M |
|
8
Soleno Therapeutics
SLNO
$3.6B
| $131M | 3.15% | 3,204,976 +130,434 | +4% | +$5.32M |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $118M | 2.83% | 1,716,407 +661,052 | +63% | +$45.3M |
|
|
10
Immatics
IMTX
$619M
| $94M | 2.26% | 8,086,159 +3,503,750 | +76% | +$40.7M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $89.5M | 2.16% | 649,909 -154,500 | -19% | -$21.3M |
|
12
Apogee Therapeutics
APGE
$2.17B
| $82.9M | 2% | 2,105,636 +45,241 | +2% | +$1.78M |
|
13
Madrigal Pharmaceuticals
MDGL
$9.76B
| $74.1M | 1.79% | 264,600 -165,353 | -38% | -$46.3M |
|
14
Artivion
AORT
$2.07B
| $71.7M | 1.73% | 2,793,703 +124,725 | +5% | +$3.2M |
|
15
Spyre Therapeutics
SYRE
$996M
| $71.3M | 1.72% | 3,031,018 +474,339 | +19% | +$11.2M |
|
16
Crinetics Pharmaceuticals
CRNX
$2.92B
| $66.1M | 1.59% | 1,476,203 | – | – |
|
17
Evolus
EOLS
$494M
| $62.4M | 1.5% | 5,753,798 | – | – |
|
|
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
| $62.3M | 1.5% | 1,652,962 -609,500 | -27% | -$23M |
|
|
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
| $60.5M | 1.46% | 3,683,004 +235,000 | +7% | +$3.86M |
|
20
Astria Therapeutics
ATXS
$349M
| $59M | 1.42% | 6,485,420 | – | – |
|
21
Natera
NTRA
$23.1B
| $57.4M | 1.38% | 530,000 -227,225 | -30% | -$24.6M |
|
22
Verrica Pharmaceuticals
VRCA
$52.8M
| $51.8M | 1.25% | 7,099,182 | – | – |
|
23
Biohaven
BHVN
$1.63B
| $51.6M | 1.24% | 1,485,232 -239,815 | -14% | -$8.32M |
|
24
Immunovant
IMVT
$2.56B
| $50.8M | 1.22% | 1,923,786 -1,039,426 | -35% | -$27.4M |
|
25
MeiraGTx Holdings
MGTX
$587M
| $47.7M | 1.15% | 11,331,103 | – | – |
|